A Placebo- and Active-Controlled Study to Evaluate the Effects of a Single-Dose and Repeat-Administration of Intranasal Esketamine on On-Road Driving in Subjects With Major Depressive Disorder (DriveSaFe2)
Phase of Trial: Phase I
Latest Information Update: 15 Mar 2018
At a glance
- Drugs Esketamine (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Acronyms DriveSaFe2
- Sponsors Janssen Research & Development
- 11 Mar 2018 Planned End Date changed from 30 Apr 2018 to 1 Oct 2018.
- 11 Mar 2018 Planned primary completion date changed from 30 Apr 2018 to 1 Aug 2018.
- 26 Oct 2016 Status changed from not yet recruiting to recruiting.